Cargando…
Loss of Efficacy of Pasireotide After its Re-Administration: is There a Reason Why?
Pasireotide is a recently approved medical treatment for persistent or recurrent Cushing’s disease (CD). However, an escape from the initial successful response has not yet been described. A 42-year-old female presented with several symptoms indicative of hypercortisolism. Biochemical evaluation and...
Autores principales: | Mandanas, Stylianos, Mathiopoulou, Lemonia, Boudina, Maria, Chrisoulidou, Alexandra, Pazaitou-Panayiotou, Kalliopi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226048/ https://www.ncbi.nlm.nih.gov/pubmed/28191290 http://dx.doi.org/10.4081/rt.2016.6489 |
Ejemplares similares
-
Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer
por: Chrisoulidou, Alexandra, et al.
Publicado: (2015) -
Parathyroid involvement in thyroid cancer: an unforeseen event
por: Chrisoulidou, Alexandra, et al.
Publicado: (2012) -
Acute adrenal insufficiency following arthroplasty: a case report and review of the literature
por: Mandanas, Stylianos, et al.
Publicado: (2013) -
Breast Metastasis from Medullary Thyroid Carcinoma in a Male Patient: Case Report and Review of the Literature
por: Mandanas, Stylianos, et al.
Publicado: (2015) -
Histological subtype is the most important determinant of survival in metastatic papillary thyroid cancer
por: Chrisoulidou, Alexandra, et al.
Publicado: (2011)